Sydney, Australia – 8th November, 2010 – HCL Technologies today announced that it has signed a deal with Novotech, the largest independent clinical research organisation in Australia, to implement Oracle’s Siebel Clinical Trial Management System (CTMS) over the next few months.
This marks HCL Technologies' first Australian life sciences customer win, following on the heels of HCL’s significant global growth in this sector through an engagement with pharmaceutical company Merck & Co.
“HCL has an excellent track record working with pharmaceutical companies globally and our partnership with Novotech further fortifies HCL’s life sciences presence in Australia. With more than 2,000 professionals servicing the ANZ region and a broad set of global, multi-vendor capabilities HCL will help Novotech to become more agile in today’s competitive environment,” said Virender Aggarwal, Executive Vice President for APAC & MEA, HCL Technologies.
The Siebel CTMS will support Novotech’s complete spectrum of clinical trial management services across Asia Pacific. In particular Siebel CTMS will
- Serve as a centralised repository to collect and track relevant information about clinical trials. The system will allow management of clinical trials at different tiers – local, regional and global;
- Offer an aggregate view of clinical trials undertaken by Novotech and provide up to date information to Novotech’s clients on project progress ; and
- Provide timely and accurate reports and dashboards to support tactical and strategic decision making.
HCL Technologies will work with Novotech in phases, starting by assessing the company’s current proprietary clinical trial management system and providing a benchmark for where the system should be in terms of scalability and flexibility. HCL will then implement and validate the Siebel CTMS and most importantly provide training to enable Novotech in using the CTMS successfully.
The work with Novotech will showcase HCL’s strength in blending project management and system validation and ensuring clear communication and feedback processes between Novotech and HCL.
“Novotech has selected HCL to be its implementation partner in this process due to its extensive experience in the Life-Sciences industry. HCL is a reliable IT partner for many Pharmaceutical & Biotech organizations across the world and comes with the right mix of business & system experience to serve our requirements. We are delighted to be involved with HCL in enhancing our infrastructure with the implementation of Oracle’s Siebel CTMS,” commented Alek Safarian, Chief Executive Officer, Novotech
HCL works with nine of the top 10 global pharmaceutical companies and two of the top global biotech companies on IT services and solutions across the value chain – from drug discovery and pre-clinical to lab automation and drug safety.
HCL is one of the early movers in the Life Sciences and Healthcare space. The Life Sciences practice at HCL started in 2002 and within a short span of time has emerged as the fastest growing vertical at HCL have an ISO 13485 certification with a y-on-y growth of over 100%.
The practice offers business aligned services in three micro-verticals: Medical Devices, Pharmaceuticals & Chemicals, and HealthCare. The core competency for the practice is Domain Consulting, Design Collaboration & Manufacturing, IT Services, BPO & Infrastructure. HCL is the First Indian Company to for design and development of medical devices and also has FDA compliant quality management system (QMS).
Headquartered in Sydney with a regional hub in Malaysia, Novotech is focused on the Asia Pacific region with operations in nine countries including India and South Korea. Novotech also has worldwide reach through the company’s network of strategic partners. Novotech, described by Frost & Sullivan as the best in its industry class for Australia based CROs, brings its global reputation for high quality service and regional expertise to the high-growth Asia Pacific area. As the largest independent CRO based in Australia, Novotech offers a level of flexibility and local knowledge that is unmatched among other contract research organisations in the region. Since 2006, Novotech has been recognised as Australia’s leading CRO by Frost & Sullivan in its Asia Pacific Excellence in Healthcare awards. For more information, please visit www.novotech-cro.com
HCL is a $5.3 billion leading global technology and IT enterprise comprising two companies listed in India - HCL Technologies and HCL Infosystems. Founded in 1976, HCL is one of India's original IT garage start-ups. A pioneer of modern computing, HCL is a global transformational enterprise today. Its range of offerings includes product engineering, custom & package applications, BPO, IT infrastructure services, IT hardware, systems integration, and distribution of information and communications technology (ICT) products across a wide range of focused industry verticals. The HCL team consists of over 71,000 professionals of diverse nationalities, who operate from 29 countries including over 500 points of presence in India. HCL has partnerships with several leading Global 1000 firms, including leading IT and technology firms. For more information, please visit www.hcl.com
About HCL Technologies
HCL Technologies is a leading global IT services company, working with clients in the areas that impact and redefine the core of their businesses. Since its inception into the global landscape after its IPO in 1999, HCL focuses on ‘transformational outsourcing’, underlined by innovation and value creation, and offers integrated portfolio of services including software-led IT solutions, remote infrastructure management, engineering and R&D services and BPO. HCL leverages its extensive global offshore infrastructure and network of offices in 29 countries to provide holistic, multi-service delivery in key industry verticals including Financial Services, Manufacturing, Consumer Services, Public Services and Healthcare. HCL takes pride in its philosophy of ‘Employee First’ which empowers our 70,218 transformers to create a real value for the customers. HCL Technologies, along with its subsidiaries, had consolidated revenues of US$ 2.9 billion (Rs. 13,145 crores), as on 30th September 2010 (on LTM basis). For more information, please visit www.hcltech.com
Certain statements in this release are forward-looking statements, which involve a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from those in such forward-looking statements. All statements, other than statements of historical fact are statements that could be deemed forward-looking statements, including but not limited to the statements containing the words 'planned,' 'expects,' 'believes,' 'strategy,' 'opportunity,' 'anticipates,' 'hopes' or other similar words. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding impact of pending regulatory proceedings, fluctuations in earnings, our ability to manage growth, intense competition in IT services, Business Process Outsourcing and consulting services including those factors which may affect our cost advantage, wage increases in India, customer acceptances of our services, products and fee structures, our ability to attract and retain highly skilled professionals, our ability to integrate acquired assets in a cost effective and timely manner, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, the success of our brand development efforts, liability for damages on our service contracts, the success of the companies /entities in which we have made strategic investments, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property, other risks, uncertainties and general economic conditions affecting our industry. There can be no assurance that the forward-looking statements made herein will prove to be accurate, and issuance of such forward-looking statements should not be regarded as a representation by the Company, or any other person, that the objective and plans of the Company will be achieved. All forward-looking statements made herein are based on information presently available to the management of the Company and the Company does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the Company.
For details, contact:
+61 451 633 719
Wilkinson Group for HCL Technologies
+61 402 183 298